1Vitali C, Bombardieri S, Jonsson R, et al. Classification criteria forSjfigrer/s syndrome : a revised version of the European criteria pro-posed by the American-European Consensus Group [ J ]. Ann RheumDis’2002,61(6) -.554 -558.
2Comec D, Jousse-Joulin S, Pers JO, et al. Contribution of salivarygland ultrasonography to the diagnosis of Sjogren,s syndrome : towardsnew diagnostic criteria. [ J] . Arthritis Rheum,2013 ,65( 1 ) :216.
3Peck AB, Nguyen CQ. Transcriptome analysis of the interferon-signa-ture defining the autoimmune process of Sjogren ^ s syndrome [ J ].Scand J Immunol ,2012,76 ( 3 ) :237 -245.
4Kajiya M,Ichimonji I,Min C,et al. Muscarinic type 3 receptor in-duces cytoprotective signaling in salivary gland cells through epider-mal growth factor receptor transactivation [ J ] . Mol Pharmacol, 2012 ,82(1):115-124.
5Iwamoto N,Kawakami A, Arima K,et al. Regulation of disease sus-ceptibility and mononuclear cell infiltration into the labial salivaryglands of SjOgem's syndrome by monocyte chemotactic protein-1[J]. Rheumatology (Oxford) ,2010,49(8) :1472 - 1478.
6Seror R, Ravaud P, Bowman SJ,et al. EULAR Sjogren^ syndromedisease activity index : development of a consensus systemic diseaseactivity index for primary Sjogren^ syndrome [ J ]. Ann Rheum Dis,2010,69(6) :1103 -1109.
